Why Big Pharma is Betting Billions to Fix the CAR-T Manufacturing Problem
For more than a decade, CAR-T cell therapy has represented one of medicine’s most exciting frontiers, a technology capable of sending certain blood cancers into lasting remission after all other treatments have failed. Yet for…
May 18, 2026
|Justin Saeks



